The effects of XXXX on the pharmacokinetics of cyclosporin A in healthy volunteers.

@entity5322 @entity7652 @entity11635 @entity870
The effects of @entity7652 (BBR) on the pharmacokinetics of @entity11635 ( @entity870 ) were examined in healthy volunteers. Six healthy male volunteers were orally treated with 0.3 g BBR, twice daily for 10 days. Pharmacokinetic investigations on @entity870 at 6 mg/kg were done both before and at the end of the BBR treatment period. Another six healthy male volunteers were involved in the pharmacokinetic study with 3 mg @entity870 /kg, in which the subjects orally received the second single dose of 3 mg @entity870 /kg, followed by a single oral dose of 0.3 g BBR. The blood @entity870 concentrations were determined by fluorescence polarization immunoassay. In the pharmacokinetic study with 6 mg @entity870 /kg, BBR caused no significant changes in the pharmacokinetic parameters of @entity870 . However, in the trial with 3 mg @entity870 /kg, the average percentage increase in area under the blood concentration-time curve of @entity870 was 19.2% (P < 0.05) and the mean C12 increased to 123 microg/l from 104 microg/l (P < 0.05), without altering elimination half-life (t(1/2)), maximum blood drug concentration (Cmax), time to Cmax (tmax), apparent oral clearance (CL/F). The present results suggest that BBR can increase the oral bioavailability of @entity870 at the dosage of 3 mg/kg. The BBR-mediated increase in @entity870 bioavailability may be partly attributed to a decrease in liver and/or intestinal metabolism through the inhibition of @entity5322 in the liver and/or gut wall. The BBR-induced increase in emptying time of stomach and small intestine might be another reason for the increase in @entity870 bioavailability. However, the speculation should be proved by further investigation.
